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Abstract
Background: Overexpression of STYK1, a putative serine/threonine and tyrosine receptor
protein kinase has been shown to confer tumorigenicity and metastatic potential to normal cells
injected into nude mice. Mutation of a tyrosine residue in the catalytic STYK1 domain attenuates
the tumorigenic potential of tumor cells in vivo, collectively, suggesting an oncogenic role for
STYK1.
Methods: To investigate the role of STYK1 expression in ovarian cancer, a panel of normal,
benign, and ovarian cancer tissues was evaluated for STYK1 immunoreactivity using STYK1
antibodies. In addition, mRNA levels were measured by reverse transcription PCR and real-time
PCR of estrogen receptors, GPR30 and STYK1 following treatment of ovarian cell lines with
estrogen or G1, a GPR30 agonist, as well as western analysis.
Results: Our data showed higher expression of STYK1 in cancer tissues versus normal or benign.
Only normal or benign, and one cancer tissue were STYK1-negative. Moreover, benign and ovarian
cancer cell lines expressed STYK1 as determined by RT-PCR. Estradiol treatment of these cells
resulted in up- and down-regulation of STYK1 despite estrogen receptor status; whereas G-1, a
GPR30-specific agonist, increased STYK1 mRNA levels higher than that of estradiol.
Conclusion: We conclude that STYK1 is expressed in ovarian cancer and is regulated by estrogen
through a GPR30 hormone-signaling pathway, to the exclusion of estrogen receptor-alpha.
Introduction
Ovarian cancer causes more deaths in women than any
other gynecological cancer. The number of deaths caused
by ovarian cancer is exacerbated by the lack of reliable
screening, specific symptoms, and effective treatments.
The National Cancer Institute estimates that 21,550 new
cases of ovarian cancer will be diagnosed in the US in
2009. Women diagnosed with localized, regional, and
distant ovarian cancer have a 93%, 69%, and 30% 5-year
survival rate, respectively [1-3]. However, diagnosis of
localized ovarian cancer only occurs in about 19% of the
cases due to a lack of reliable screening techniques and the
absence of specific symptoms.
Ovarian cancer samples overexpress a putative serine-thre-
onine receptor protein kinase, STYK1, as demonstrated by
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shares approximately 30-34% identity with FGFR (fibrob-
last growth factor receptor)/PDGFR (platelet-derived
growth factor) family members, which have been shown
to function as oncogenes [5]. STYK1 overexpression con-
stitutively activated the RAS/MAPK, STAT1, and STAT3
pathways in NIH3T3 cells [6]. Interestingly, ovarian can-
cer cells were shown to constitutively express high levels
of STAT3 [7,8]. Furthermore, BaF3 cell lines overexpress-
ing STYK1 proliferated in media without serum or growth
factors. Inoculation of these cells into nude mice induced
tumor formation within one week and the cells metasta-
sized after 4 weeks. Introducing a tyrosine to phenyla-
lanine point mutation into the catalytic domain of STYK1
blocked cell proliferation as well as STYK1-induced tum-
origenesis [6,9]. STYK1 expression is regulated by estrogen
in ERα (estrogen receptor alpha)-negative (MDA-MB-
231) and ERα-positive MCF7) breast cancer cells based on
microarray analysis and real-time PCR analysis [10].
Estrogen receptors play a critical role in ovarian tumor cell
growth. Ovarian surface epithelial cells produce estradiol
and estrone, and the ovary is a key target of estrogen [11].
The postmenopausal ovary produces little or no estrogen;
conversely, increased steroid hormone levels have been
observed in the plasma of ovarian cancer patients [12].
The occurrence of ovarian cancer increases dramatically in
menopausal women. Furthermore, previous studies
report a correlation between plasma estradiol, progester-
one, and androstenedione with stage of disease [13,14].
However, the mechanisms by which estrogen receptors
contribute to ovarian tumorigenesis are still unclear [4].
GPR30, a novel estrogen receptor, and ERα stimulation by
both G-1 (GPR30-specific ligand) and estradiol were
shown to synergistically induce proliferation of breast and
ovarian cancer lines [15].
In this study we examined STYK1 immunoreactivity in
normal, benign, and malignant ovarian tissues. To inves-
tigate the role of estrogen and GPR30 in STYK1 regulation,
we treated a benign and several malignant ovarian cancer
cell lines with estradiol and G-1. We describe differences
in STYK1 RNA and protein expression levels in treated ver-
sus untreated ovarian tumor cells. We also compare estra-
diol- and G-1-induced STYK1 expression. In the present
report, we show that STYK1 expression is associated with
ovarian tumorigenesis. Furthermore, we provide evidence
for estrogen-mediated STYK1 regulation through an
unknown GPR30 signaling pathway.
Materials and methods
Chemicals
17β-estradiol and BSA-conjugated estradiol were pur-
chased from Sigma-Aldrich (Sigma, St. Louis, MO). 1-(4-
(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta [c]quinolin-8-yl)-ethanone (G-1) was pur-
chased from Calbiochem (San Diego, CA).
Antibodies
STYK1 and GPR30 antibodies were purchased from
AbCam (Cambridge, MA). α-Tubulin antibody was pur-
chased from Millipore (Billerica, MA).
Cell culture
HS832, OvCar3, and CaOv3 were obtained from Ameri-
can Type Culture Collection (Manassas, VA). SkOv3,
OvCar5, OvCar8, and IGROV1 were kindly provided by
the lab of Dr. Neil Sidell (Emory University School of
Medicine, Department of Gynecology and Obstetrics). All
cell lines were maintained in DMEM with 10% FBS. Prior
to treatment the cells were incubated in phenol-red free
DMEM supplemented with 20% charcoal stripped FBS
overnight (12-16 h) followed by incubation with 5 × 10-8
M estradiol, 1 × 10-8 M BSA-conjugated estradiol, and 1 ×
10-8 M G-1 for 4-18 h. Ethanol, phosphate-buffered saline
(PBS), and dimethyl sulfoxide were used as the respective
vehicle controls.
Reverse transcriptase (RT) and real time RT-PCR
Treated and untreated cells were rinsed with PBS and pel-
leted for RNA isolation. RNA was extracted using the RNe-
asy Midi kit (Qiagen Inc., Valencia, CA) according to the
manufacturer's instructions. RNA purity and concentra-
tion were determined by spectrophotometry. cDNA was
generated at a concentration equivalent to 25 ng/μL of
RNA in a 20 μL volume with random hexamers and Super-
script II reverse transcriptase (Invitrogen Corporation).
The PCR products were visualized on ethidium bromide-
stained 2% agarose gels under UV light. Real-time PCR
was carried out using the ABI Prism 7000 System. Tubulin
was used as an internal control for normalization of each
data point. Relative induction was calculated using the 2-
ΔΔCT formula [16]. RNA was analyzed from three inde-
pendent experiments.
Western blotting
Lysates were collected from treated and untreated cells in
modified radioimmuno precipitation assay (RIPA) buffer
containing EDTA and a protease inhibitor cocktail (Pierce
Biotechnology, Rockford, IL) by standard methods. 40 μg
of protein was resolved by SDS-PAGE and transferred
onto PVDF membranes. The membranes were subjected
to immunodetection by incubation with primary anti-
body for STYK1 (1:500) and GPR30 (1:250). Equal pro-
tein loading was controlled by immunoblot of α-tubulin
(1:3000). The lysates from three independent experi-
ments were analyzed.Page 2 of 7
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Formalin-fixed arrays of normal, benign, and malignant
ovarian tissues were obtained from Pantomics Inc. (San
Franscico, CA). The tissues were stained with a mouse
monoclonal antibody for STYK1 and counterstained with
hematoxylin by the Winship Cancer Institute Pathology
Core Facility at Emory University. Each tissue section was
assigned a score of 0 for none, 1 for weak, 2 for moderate,
or 3 for strong STYK1 immunoreactivity. Scoring of the tis-
sue sections was done by one of the authors without prior
knowledge of the clinical parameters.
Statistical analysis
Statistical analyses were performed using the one-way
ANOVA test in GraphPad Prism (San Diego, CA). The data
are presented as mean ± standard error.
Results
Expression of STYK1 in normal, benign, and malignant 
ovarian tissues
Each normal ovarian tissue section was negative for
STYK1 immunoreactivity (Fig. 1A). Although several of
the benign ovarian tissue sections were positive for STYK1
immunoreactivity the staining intensity was weak (repre-
sented by the staining in normal tissue). The remaining
benign ovarian tissues as well as one malignant ovary
showed no STYK1 immunoreactivity. Many of the ovarian
cancer tissue sections had weak STYK1 staining intensity
as seen in the benign tissues, however, moderate and
strong STYK1 staining intensity was seen only in the
malignant ovarian tissues (i.e. endometroid adenocarci-
nomas). STYK1 immunoreactivity was cytoplasmic in
every STYK1-positive ovarian tissue section (Fig. 1B).
STYK1 Protein Expression is Associated with Ovarian CancerFigure 1
STYK1 Protein Expression is Associated with Ovarian Cancer. An ovarian tissue array (Pantomics, Inc.) was stained 
with STYK1 antibody. (A) Each tissue section was assigned a score of 0 for no staining, 1 for weak, 2 for moderate, or 3 for 
strong STYK1 reactivity. (B) STYK1 localizes to the cytoplasm in malignant ovarian tissues. Representative of sections (20× 
magnification) immunohistochemical stains of normal and endometroid adenocarcinomas with anti-STYK1 antibody shown, 
from left to right, no staining (a), weak (b), and moderate staining (c).Page 3 of 7
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cancer cell lines
We detected ER-  RNA expression in ovarian cancer cell
lines SKOV3, CaOv3, and OvCar3 (Fig. 2A). Cell lines
HS832, OvCar5, OvCar8 and IGROV had no detectable
ER  transcript. While ER  expression was weak for most of
the cell lines, no expression was detected in HS832 and
IGROV1 cells. Every cell line expressed GPR30; however,
strong expression was seen only in HS832, OvCar5,
OvCar8, and IGROV1. GPR30 and STYK1 protein was
detected at varying levels in each cell line (Fig. 2B).
Estradiol and GPR30-specific G-1 induce STYK1 RNA but 
not protein expression in ovarian cancer cell lines
RNA isolated from estradiol-treated HS832, OvCar5,
OvCar8, and SkOv3 cells was analyzed by real time RT-
PCR with STYK1 primers. STYK1 expression increased sig-
nificantly (p < 0.001) in HS832 cells (ER  neg., ER-  neg.,
GPR30 pos.) and decreased by almost half in the SkOv3
cells (ER  pos., ER-  pos., GPR30 pos.) after 18 hours in the
presence of estradiol (Fig. 3A). While STYK1 expression
decreased slightly in OvCar5 cells (ER  neg., ER-  pos.,
GPR30 pos.), there was no real change in expression in
OvCar8 cells, which have the same ER expression profile.
HS832, OvCar5, and SkOv3 cells treated (16 hours) with
G-1, a GPR30-specific ligand, showed an increase in
STYK1 expression relative to 16 hours estradiol-treated
cells although the increase was only significant in OvCar5
cells (p < 0.001; Fig. 3B). Conversely, STYK1 expression
decreased slightly in G-1-treated OvCar8 cells. When the
cells were treated with BSA-conjugated estradiol (E2B),
which allows estradiol to interact with receptors on the
cell membrane but prevents the molecule from entering
the cell, STYK1 expression increased relative to estradiol-
induced expression in OvCar5 cells but decreased in
OvCar8 cells. There was no appreciable change in STYK1
expression in HS832 and SkOv3 cells. In contrast to
STYK1 RNA expression, STYK1 protein expression levels
were unaffected by estradiol, BSA-conjugated estradiol,
and G-1 treatments, with the possible exception of
OvCar5, where a slight increase in STYK1 was observed
with E2B after 16 hours post-treatment (Fig. 4).
Discussion and Conclusion
STYK1 mRNA levels have been reported in human benign
and/or malignant tissues, but the immunoreactivity of
STYK1 has not been reported. Several reports demonstrate
STYK1 mRNA expression in various normal tissues and
STYK1 overexpression in breast and lung cancer tissues
and cell lines, as well as in patients with acute leukemia
[17-19]. Moreover, Moriai et. al reported high levels of
STYK1 expression even in early stages of breast cancer. In
this study, we demonstrated the presence of STYK1 immu-
noreactivity, in benign and malignant ovarian tissues and
cell lines but not in normal ovarian tissue. Moreover,
benign ovarian tissues displaying immunoreactivity for
STYK1 displayed weak staining. Moderate and strong
STYK1 staining was seen only in the high grade ovarian
cancer tissues. This data suggests that STYK1 is associated
with tumorigenic and malignant phenotypes in ovarian
tissue. However, it should be noted that duplicates of only
two normal tissue sections were analyzed in this study.
With more samples this data should support the need for
future studies to validate STYK1 as a potential prognostic
tool for detecting multiple stages of ovarian carcinogene-
sis.
Our lab previously demonstrated that estradiol increases
STYK1 mRNA levels in ER  negative, ER  positive MDA-MB
231 breast cancer cells [10]. In the current study estradiol
downregulated STYK1 in OvCar5 cells expressing ERβ but
not ERα but did not have a notable affect on STYK1
mRNA levels in OvCar8 cells, which have the same estro-
gen receptor expression profile (Fig. 3A). This might be
due to the presence of higher levels of GPR30 downstream
signaling proteins or EGFR/HER protein levels, which are
involved in signaling through GPR30. This would be sup-
ported in the increase of STYK1 due to G1 treatment,
OvCar5 versus OvCar8. It is notable that the level of
GPR30 mRNA is not reflective of the relative levels of
GPR30 protein. Further investigation into the mechanism
Ovarian tumor cell lines express STYK1 and variably express estrogen receptorsFigur  2
Ovarian tumor cell lines express STYK1 and variably 
express estrogen receptors. HS832 is a benign ovarian 
cell line and the remaining cell lines were derived from ovar-
ian cancer cell lines. (A) Ethidium bromide-induced fluores-
cence of RT-PCR amplification product from ovarian tumor 
RNA using primers for ERα, ERβ, GPR30, and STYK1. Tubu-
lin primers were used as a loading control; (B) STYK1 and 
GPR30 protein expression. The western blot was stripped 
and re-probed with α-tubulin antibody as a loading control.Page 4 of 7
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Estradiol and G-1 induce STYK1 RNA expressionFigure 3
Estradiol and G-1 induce STYK1 RNA expression. Ovarian tumor cell lines were treated with vehicle, 5 × 10-8 M estra-
diol, 1 × 10-8 M BSA-conjugated estradiol (E2B), and 1 × 10-8 M G-1 for 4-18 h(T4, T8, T18). cDNA equivalent to 25 ng/μL of 
RNA was generated and analyzed by real-time RT-PCR. Relative values were normalized to α-tubulin and values were com-
pared to the vehicle. Values are the mean of 3 independent experiments. (A) STYK1 induction in estradiol-treated ovarian 
tumor cells relative to untreated cells for various intervals; (B) STYK1 induction in E2-, E2B- and G1-treated cells relative to 
estradiol-induced STYK1 expression following 18 hours. * and ** indicate values that are significantly different compared to the 
vehicle (p < 0.01 and p < 0.001, respectively).
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ever, the higher ERβ levels in the OvCar8 cells could
account for the difference in STYK1 regulation. Interest-
ingly, the highest STYK1 induction was seen in the HS832
cells (8 h, p < 0.01; 18 h, p < 0.001), which are ER  and ER
negative while the ER  and ER  positive SkOv3 cells had a
marked reduction in STYK1 expression in response to
estradiol treatment. This data suggests that there is an
inverse relationship between estradiol-mediated STYK1
regulation and ER /ER  expression. A similar observation
was observed in MCF7, ERα positive, ERβ negative versus
MDA-MB-231 which is ERα negative, ERβ positive [10].
ER  was previously shown to downregulate the FN1 gene
in ovarian cancer cells and ERβ expression is inversely cor-
related with tumorigenesis in ovarian cells [11,20]. Regu-
lation of STYK1 expression in cells negative for ER  and
ER  points to estradiol-mediated regulation through a
nontraditional hormone receptor pathway, possibility
GPR30.
GPR30, a novel estrogen receptor was recently reported to
mediate changes in gene expression and growth in ovar-
ian cancer cells treated with estradiol [15]. We showed
that G-1, a GPR30-specific ligand, induced STYK1 at a
higher level in the ovarian tumor cells than estradiol. A
significant increase (p < 0.001) in G-1-induced STYK1
expression was seen in OvCar5 cells, which do not express
ER , the primary estradiol receptor, but expresses ERβ at
very weak levels. In contrast, G-1 downregulated STYK1 in
OvCar8 cells, which expressed no ERα and the highest
ERβ levels of the analyzed cell lines. We speculate that
STYK1 is a downstream target of estrogen-mediated
GPR30 activation in ovarian cancer cells and that the
affect of GPR30 on STYK1 expression is more pronounced
in the absence of ER  and ER . This difference in STYK1
regulation could be due to the loss preferential or compet-
itive binding of estradiol to ER  and/or ER . It is important
to note that one study reported that estradiol does not
activate GPR30 [21]. It would also imply that the affect
ER  and/or ER  on GPR30-mediated regulation of STYK1
expression occurs through a mechanism other than com-
petitive ligand binding.
The cellular localization of GPR30 is controversial. It has
been reported to localize to the cell membrane and the
endoplasmic reticulum membrane [21,22]. We addressed
this issue; G-1-induced STYK1 expression was compared
to that in cells treated with BSA-conjugated estradiol
(E2B), which is too large to enter the cell. Therefore, any
estradiol-induced STYK1 expression would occur through
binding of estradiol to a cell membrane receptor. E2B
induced STYK1 expression at a level similar to the estra-
diol induction in each cell line except OvCar5, where
STYK1 expression doubled. However, E2B-induction was
consistently lower than that seen in G-1-treated cells. This
data supports localization of GPR30 to the cell membrane
but does not controvert reports of its intracellular localiza-
tion and provides further evidence of estradiol binding to
GPR30.
Liu et. al reported tumorigenesis and metastasis of normal
cells (NIH3T3 and BaF3) overexpressing STYK1 in nude
mice [5]. Their group suggested that abnormal expression
of STYK1 results in a constitutively active state caused by
disruption of an inactive vs. active state equilibrium.
However, we did not see an appreciable difference in total
STYK1 protein expression is unaffected by estradiol and G-1 treatmentFigure 4
STYK1 protein expression is unaffected by estradiol and G-1 treatment. Ovarian tumor cell lines were treated with 
vehicle, 5 × 10-8 M estradiol, 1 × 10-8 M BSA-conjugated estradiol (E2B), and 1 × 10-8 M G-1 for 4-18 h for 18 hours. Forty μg 
of protein lysate from the indicated cell lines were electrophoresed by 12.5% SDS PAGE and transferred to PVDF membrane. 
The blot was probed with anti-STYK1 antibody then stripped and re-probed with α-tubulin as a loading control. This is a rep-
resentative blot from three independent experiments. * indicates a value that is significantly different compared to 5 × 10-8 M 
estradiol treatment (p < 0.001).Page 6 of 7
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STYK1 protein levels in cells treated with estradiol and G-
1 compared to untreated controls. It is possible that
changes in STYK1 protein levels occur early in tumorigen-
esis and that estradiol does not further induce STYK1 over-
expression. Nonetheless, studies show that STYK1 activity
is regulated by phosphorylation and dephosphorylation
of several tyrosine residues within exon 11 [6,9]. There-
fore, both STYK1 and GPR30 might be model therapeutic
targets for the development of more effective ovarian can-
cer treatments. These molecular targets may also be espe-
cially important in treating triple negative (ER  negative,
HER2 negative, progesterone receptor negative) breast
cancers, which are often nonresponsive to standard chem-
otherapeutic medications that target traditional hormone
receptors [10].
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